contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


revenio-exceptionally-strong-figures-supported-dollar

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Juha Kinnunen

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Inderes              Muutos F-Securen johtoryhmässä – Talousjohtaja vaihtuu - Inderes    Muutos F-Securen johtoryhmässä – Talousjohtaja vaihtuuF-Secure Oyj | Pörssitiedote | 18.12.2025 klo 9.00F-Securen talousjohtaja ja johtoryhmän jäsen Sari Somerkallio on päättänyt jättää F-Securen...                             Robin seems to be joining F-Secure

Jouni and Robin were a powerful duo. They inspired trust when you met them. It’s difficult to find a replacement, but let’s hope for the best.

CFO Robin Pulkkinen is leaving Revenio. I had discussions with Robin at general meetings for about 10 years. An extremely competent guy, the acquisition of Centervue together with Hilden was a great value-creating move for shareholders. A shame.                   Tärkeimmät talousuutiset | Kauppalehti – 18 Dec 25              Muutos johtoryhmässä: Robin Pulkkinen jättää tehtävänsä    Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä.

Good morning! Thanks for the good question @MolskisPabrai - I’ll find out what that could mean in practice and get back to you as soon as possible.

The FDA has announced this week that it is changing its practices regarding medical device approval applications. Device manufacturers can now more broadly use de-identified real-world data in their approval applications, and do not necessarily always have to conduct expensive clinical trials, at least not as extensively as now. @Juha_Kinnunen, could this have an impact on getting AI product approvals faster in the US? Why not also on the possible expansion of approvals for HOME2 or other iCare products, if such are being sought. However, Revenio, to my understanding, has a lot of this real-world data in the iCare CLINIC cloud. Edit: As an addition, is Revenio the only one with access to a massive amount of de-identified data through HOME2 measurements, or do Reichert or others have a similar cloud? If Revenio is the only one, this could be a significant competitive advantage.

Q3 was indeed rather boring, and it seems Q4 is progressing along the same lines. Reve also keeps a lower profile than before; they didn’t even bother to attend last week’s investor fair. We’ve met Salovaara and Hilden many times at that forum, but perhaps they no longer feel it necessary to meet us profit/information-hungry “slipper-wearers” with our difficult questions. A large foreign owner, of course, happily snaps up more shares as small investors look for alternative targets, of which there were indeed many at the exhibition center. Indeed, this M&A story has been heard for quite a long time, and the discussion may continue if/when high valuations have been the problem. Many stock markets have been rising for a couple of years now, and it’s unlikely that any significant discounts on asking prices will be coming anytime soon, rather the opposite. This global leader in ophthalmological devices and software solutions (according to its website) is now, at least from the window of my own sauna, somewhat in hibernation. Besides, a leading company in the field should have already had that much-talked-about OCT camera. The esteemed forum guru Optis has been reminding us of this for years, but now even the man on the street is starting to encounter OCT advertising in optician store windows. Well, I guess there’s nothing for it but to start building that OCT myself. I asked the AI for some advice: ’’Yes, it is possible to buy OCT sensors and the individual components required to build or customize an OCT system. While full commercial medical systems are typically expensive and proprietary, components are readily available for researchers, OEMs, and custom system builders. Where to Buy OCT Components Several specialized suppliers cater to the research and development market:   Thorlabs, Inc.: This company is a major supplier of complete OCT systems, subsystems, and individual components (e.g., light sources, beam scanning systems, scan lens kits) for custom builds in research and industrial applications. You can explore their offerings on the Thorlabs website.   Wasatch Photonics: They offer preconfigured, high-performance OCT spectrometers (a key sensor component) at various wavelengths and speeds, making system design easier for OEMs and researchers who don’t want to build every part from scratch.   OZ Optics Ltd.: This company provides a variety of passive and active fiber optic components, including superluminescent diode (SLD) light sources and broadband fiber components, used specifically for building OCT systems.   Edmund Optics: A supplier of various optical components and systems, including Lumedica OCT imaging systems.   OEM Suppliers (e.g., JADAK, G&H, Santec): Many companies offer OEM solutions, providing customized sensors, modules, and components for integration into larger commercial products.   These specialized suppliers offer OCT system components and configurable OCT systems for various applications:   Key Considerations   “Build vs. Buy”: Purchasing pre-optimized modules can save significant time and effort in optical design, alignment, and software development compared to sourcing every single piece independently.   Application Specific: Components are specialized for either spectral-domain (SD-OCT) or swept-source (SS-OCT) technology, and the required wavelength will depend on the application (e.g., 850 nm and 1060 nm are popular for medical use).   Expertise Required: Assembling a functional OCT system from individual sensors and components typically requires significant expertise in optics, engineering, and software development.   So, in Finnish: “it’s no big deal”. Let’s see if I can solder the package together before Revenio

Revenio’s trading volume today, with a rising share price, is many times higher than normal. Those in the know, know, I don’t…

Revenio Group

Revenio entered Q2 in its typical manner, delivering an excellent result, but the majority of the overperformance came from exchange rate effects. 

<p>Revenio entered Q2 in its typical manner, delivering an excellent result, but the majority of the overperformance came from exchange rate effects. We raised our estimates for the current year, as EUR/USD rates support earnings, but next year's estimates remain unaffected. Revenio is among the elite of Nasdaq Helsinki in terms of continuous value creation, but the stock is also valued at a superstar level (2023e P/E around 50x). As a result, the expected return remains rather weak, and we don’t see any justification for further purchases.</p> 

	2021	22e	23e
Revenue	78.8	99.9	116.3
growth-%	29.1 %	26.8 %	16.4 %
EBIT (adj.)	24.5	32.5	38.4
EBIT-% (adj.)	31.1 %	32.5 %	33.0 %
EPS (adj.)	0.74	0.97	1.11
Dividend	0.34	0.51	0.58
Dividend %	0.6 %	2.3 %	2.6 %
P/E (adj.)	75.1	22.9	19.9
EV/EBITDA	57.7	16.8	14.1

Revenio: Exceptionally strong figures supported by the dollar

Key Estimate Figures05.08.2022

Forum discussions